RAMP 301, NCT06072781: A Study of Avutometinib (VS-6766) + Defactinib (VS-6063) in Recurrent Low-Grade Serous Ovarian Cancer |
|
|
| Recruiting | 3 | 270 | Europe, Canada, US, RoW | avutometinib, avutometinib (VS-6766), Defactinib, defactinib (VS-6063), Pegylated liposomal doxorubicin, Caelyx, Doxil, Lipodox, Paclitaxel, Nov-Onxol, Onxol, Navaplus, Taxol, Letrozole, Femara, Anastrozole, Arimidex | Verastem, Inc., GOG Foundation, European Network of Gynaecological Oncological Trial Groups (ENGOT), Australia New Zealand Gynaecological Oncology Group | Low Grade Serous Ovarian Cancer | 10/28 | 02/31 | | |
| Terminated | 2 | 83 | Europe | Niraparib, Zejula | Mario Negri Institute for Pharmacological Research, North Eastern German Society of Gynaecological Oncology | Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinoma | 08/24 | 08/24 | | |
N-Plus, NCT05460000: A Phase II Randomized, Open Label Non-inferiority Study of NiraParib Maintenance After 3 vs. 6 Cycles of Platinum-based Chemotherapy in completeLy debUlked Advanced HRDpositive High-grade Ovarian Cancer patientS in First Line Therapy |
|
|
| Recruiting | 2 | 640 | Europe | 3 cycles chemotherapy instead of 6 cycles chemotherapy, 6 cycles chemotherapy | North Eastern German Society of Gynaecological Oncology, Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinoma, Clear Cell Carcinoma | 05/27 | 05/32 | | |
